189 related articles for article (PubMed ID: 21735094)
1. A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase.
Kinoshita T; Sekiguchi Y; Fukada H; Nakaniwa T; Tada T; Nakamura S; Kitaura K; Ohno H; Suzuki Y; Hirasawa A; Nakanishi I; Tsujimoto G
Mol Cell Biochem; 2011 Oct; 356(1-2):97-105. PubMed ID: 21735094
[TBL] [Abstract][Full Text] [Related]
2. Structural and Mechanistic Basis of the Inhibitory Potency of Selected 2-Aminothiazole Compounds on Protein Kinase CK2.
Lindenblatt D; Nickelsen A; Applegate VM; Jose J; Niefind K
J Med Chem; 2020 Jul; 63(14):7766-7772. PubMed ID: 32589844
[TBL] [Abstract][Full Text] [Related]
3. Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
Sekiguchi Y; Nakaniwa T; Kinoshita T; Nakanishi I; Kitaura K; Hirasawa A; Tsujimoto G; Tada T
Bioorg Med Chem Lett; 2009 Jun; 19(11):2920-3. PubMed ID: 19414254
[TBL] [Abstract][Full Text] [Related]
4. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic activity with an incomplete catalytic spine: insights from a comparative structural analysis of human CK2α and its paralogous isoform CK2α'.
Bischoff N; Raaf J; Olsen B; Bretner M; Issinger OG; Niefind K
Mol Cell Biochem; 2011 Oct; 356(1-2):57-65. PubMed ID: 21739153
[TBL] [Abstract][Full Text] [Related]
6. Conformational plasticity of the catalytic subunit of protein kinase CK2 and its consequences for regulation and drug design.
Niefind K; Issinger OG
Biochim Biophys Acta; 2010 Mar; 1804(3):484-92. PubMed ID: 19796713
[TBL] [Abstract][Full Text] [Related]
7. Molecular Plasticity of Crystalline CK2α' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity.
Lindenblatt D; Applegate V; Nickelsen A; Klußmann M; Neundorf I; Götz C; Jose J; Niefind K
J Med Chem; 2022 Jan; 65(2):1302-1312. PubMed ID: 34323071
[TBL] [Abstract][Full Text] [Related]
8. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
Bollacke A; Nienberg C; Borgne ML; Jose J
J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
[TBL] [Abstract][Full Text] [Related]
9. Conformational dynamics of human protein kinase CK2α and its effect on function and inhibition.
Srivastava A; Hirota T; Irle S; Tama F
Proteins; 2018 Mar; 86(3):344-353. PubMed ID: 29243286
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.
Patel S; Vyas VK; Sharma M; Ghate M
Future Med Chem; 2023 Jun; 15(11):987-1014. PubMed ID: 37307219
[TBL] [Abstract][Full Text] [Related]
11. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
12. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.
Brear P; Ball D; Stott K; D'Arcy S; Hyvönen M
J Med Chem; 2020 Nov; 63(21):12786-12798. PubMed ID: 33119282
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
14. Structure of human protein kinase CK2 alpha 2 with a potent indazole-derivative inhibitor.
Nakaniwa T; Kinoshita T; Sekiguchi Y; Tada T; Nakanishi I; Kitaura K; Suzuki Y; Ohno H; Hirasawa A; Tsujimoto G
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Feb; 65(Pt 2):75-9. PubMed ID: 19193990
[TBL] [Abstract][Full Text] [Related]
15. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R
Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
Schnitzler A; Niefind K
Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
[TBL] [Abstract][Full Text] [Related]
17. Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2.
Pietsch M; Viht K; Schnitzler A; Ekambaram R; Steinkrüger M; Enkvist E; Nienberg C; Nickelsen A; Lauwers M; Jose J; Uri A; Niefind K
Bioorg Chem; 2020 Mar; 96():103608. PubMed ID: 32058103
[TBL] [Abstract][Full Text] [Related]
18. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
19. First inactive conformation of CK2 alpha, the catalytic subunit of protein kinase CK2.
Raaf J; Issinger OG; Niefind K
J Mol Biol; 2009 Mar; 386(5):1212-21. PubMed ID: 19361447
[TBL] [Abstract][Full Text] [Related]
20. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin.
Raaf J; Klopffleisch K; Issinger OG; Niefind K
J Mol Biol; 2008 Mar; 377(1):1-8. PubMed ID: 18242640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
